JP7120717B2 - 多重ｒｎａ誘導型ゲノム編集 - Google Patents

多重ｒｎａ誘導型ゲノム編集 Download PDF

Info

Publication number
JP7120717B2
JP7120717B2 JP2016525411A JP2016525411A JP7120717B2 JP 7120717 B2 JP7120717 B2 JP 7120717B2 JP 2016525411 A JP2016525411 A JP 2016525411A JP 2016525411 A JP2016525411 A JP 2016525411A JP 7120717 B2 JP7120717 B2 JP 7120717B2
Authority
JP
Japan
Prior art keywords
dna
cells
nucleic acid
strain
exogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016525411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523559A (ja
JPWO2015006290A5 (enExample
JP2016523559A5 (enExample
Inventor
ジョージ、 エム． チャーチ、
ジェームス ディカーロ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2016523559A publication Critical patent/JP2016523559A/ja
Publication of JP2016523559A5 publication Critical patent/JP2016523559A5/ja
Publication of JPWO2015006290A5 publication Critical patent/JPWO2015006290A5/ja
Application granted granted Critical
Publication of JP7120717B2 publication Critical patent/JP7120717B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Crystallography & Structural Chemistry (AREA)
JP2016525411A 2013-07-09 2014-07-08 多重ｒｎａ誘導型ゲノム編集 Active JP7120717B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844168P 2013-07-09 2013-07-09
US61/844,168 2013-07-09
PCT/US2014/045691 WO2015006290A1 (en) 2013-07-09 2014-07-08 Multiplex rna-guided genome engineering

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019238862A Division JP7201294B2 (ja) 2013-07-09 2019-12-27 多重ｒｎａ誘導型ゲノム編集

Publications (4)

Publication Number Publication Date
JP2016523559A JP2016523559A (ja) 2016-08-12
JP2016523559A5 JP2016523559A5 (enExample) 2017-07-27
JPWO2015006290A5 JPWO2015006290A5 (enExample) 2022-02-07
JP7120717B2 true JP7120717B2 (ja) 2022-08-17

Family

ID=52280509

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016525411A Active JP7120717B2 (ja) 2013-07-09 2014-07-08 多重ｒｎａ誘導型ゲノム編集
JP2019238862A Active JP7201294B2 (ja) 2013-07-09 2019-12-27 多重ｒｎａ誘導型ゲノム編集
JP2022202204A Active JP7676351B2 (ja) 2013-07-09 2022-12-19 多重ｒｎａ誘導型ゲノム編集
JP2024087738A Pending JP2024109929A (ja) 2013-07-09 2024-05-30 多重ｒｎａ誘導型ゲノム編集

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019238862A Active JP7201294B2 (ja) 2013-07-09 2019-12-27 多重ｒｎａ誘導型ゲノム編集
JP2022202204A Active JP7676351B2 (ja) 2013-07-09 2022-12-19 多重ｒｎａ誘導型ゲノム編集
JP2024087738A Pending JP2024109929A (ja) 2013-07-09 2024-05-30 多重ｒｎａ誘導型ゲノム編集

Country Status (12)

Country Link
US (2) US11459585B2 (enExample)
EP (2) EP4166669A1 (enExample)
JP (4) JP7120717B2 (enExample)
KR (3) KR20220025922A (enExample)
CN (2) CN116042726A (enExample)
AU (3) AU2014287393B2 (enExample)
CA (2) CA2917638C (enExample)
ES (1) ES2929143T3 (enExample)
IL (2) IL303973A (enExample)
RU (2) RU2706562C2 (enExample)
SG (3) SG10201913026TA (enExample)
WO (1) WO2015006290A1 (enExample)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
EP4282970A3 (en) * 2012-12-17 2024-01-17 President and Fellows of Harvard College Rna-guided human genome engineering
EP3919505B1 (en) 2013-01-16 2023-08-30 Emory University Uses of cas9-nucleic acid complexes
EP3456831B1 (en) 2013-04-16 2021-07-14 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
EP3611268A1 (en) 2013-08-22 2020-02-19 E. I. du Pont de Nemours and Company Plant genome modification using guide rna/cas endonuclease systems and methods of use
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
EP3988649B1 (en) 2013-09-18 2024-11-27 Kymab Limited Methods, cells and organisms
KR20230054509A (ko) 2013-11-07 2023-04-24 에디타스 메디신, 인코포레이티드 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
AU2015217208B2 (en) 2014-02-11 2018-08-30 The Regents Of The University Of Colorado, A Body Corporate CRISPR enabled multiplexed genome engineering
WO2015134812A1 (en) 2014-03-05 2015-09-11 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3553176A1 (en) 2014-03-10 2019-10-16 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3122880B1 (en) 2014-03-26 2021-05-05 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
EP3540061A1 (en) 2014-04-02 2019-09-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating primary open angle glaucoma
MX2016014066A (es) 2014-04-28 2017-05-03 Recombinetics Inc Edicion de genes multiples en cerdos.
US20160060655A1 (en) 2014-05-30 2016-03-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods to treat latent viral infections
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
AU2015342749B2 (en) 2014-11-07 2022-01-27 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
CN107250148B (zh) 2014-12-03 2021-04-16 安捷伦科技有限公司 具有化学修饰的指导rna
WO2016123514A1 (en) * 2015-01-29 2016-08-04 University Of Massachusetts Nanoparticle-protein complex for intracellular protein delivery
AU2016232819B2 (en) 2015-03-19 2021-10-21 Board Of Regents Of The University Of Texas System Compositions and methods for use of anion channel rhodopsins
ES2884838T3 (es) 2015-04-06 2021-12-13 Univ Leland Stanford Junior ARN guía químicamente modificados para la regulación génica mediada por CRISPR/CAS
JP2018522249A (ja) 2015-04-24 2018-08-09 エディタス・メディシン、インコーポレイテッド Ｃａｓ９分子／ガイドｒｎａ分子複合体の評価
EP4008780A1 (en) * 2015-04-30 2022-06-08 The Trustees of Columbia University in the City of New York Gene therapy for autosomal dominant diseases
WO2016179038A1 (en) * 2015-05-01 2016-11-10 Spark Therapeutics, Inc. ADENO-ASSOCIATED VIRUS-MEDIATED CRISPR-Cas9 TREATMENT OF OCULAR DISEASE
EP3294896A1 (en) 2015-05-11 2018-03-21 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
KR102553518B1 (ko) 2015-06-01 2023-07-07 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Hiv 감염의 rna-가이드된 치료를 위한 방법 및 조성물
WO2016201047A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
ES2905558T3 (es) 2015-11-13 2022-04-11 Avellino Lab Usa Inc Procedimientos para el tratamiento de las distrofias corneales
EP3433363A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP3433364A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
EP4047092B1 (en) 2016-04-13 2025-07-30 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
WO2017207589A1 (en) 2016-06-01 2017-12-07 Kws Saat Se Hybrid nucleic acid sequences for genome engineering
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
DK3474669T3 (da) 2016-06-24 2022-06-27 Univ Colorado Regents Fremgangsmåde til generering af stregkodede kombinatoriske biblioteker
US10669558B2 (en) 2016-07-01 2020-06-02 Microsoft Technology Licensing, Llc Storage through iterative DNA editing
US11359234B2 (en) 2016-07-01 2022-06-14 Microsoft Technology Licensing, Llc Barcoding sequences for identification of gene expression
US10892034B2 (en) 2016-07-01 2021-01-12 Microsoft Technology Licensing, Llc Use of homology direct repair to record timing of a molecular event
JP7004651B2 (ja) * 2016-07-19 2022-02-04 株式会社バイオダイナミクス研究所 長鎖一本鎖ｄｎａを調製する方法
WO2018026976A1 (en) 2016-08-02 2018-02-08 Editas Medicine, Inc. Compositions and methods for treating cep290 associated disease
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
US20190185850A1 (en) * 2016-08-20 2019-06-20 Avellino Lab Usa, Inc. Single guide rna/crispr/cas9 systems, and methods of use thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US12286727B2 (en) 2016-12-19 2025-04-29 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3565907B1 (en) 2017-01-06 2022-05-04 Editas Medicine, Inc. Methods of assessing nuclease cleavage
US20190352626A1 (en) * 2017-01-30 2019-11-21 KWS SAAT SE & Co. KGaA Repair template linkage to endonucleases for genome engineering
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US12058986B2 (en) 2017-04-20 2024-08-13 Egenesis, Inc. Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements
EP3615672A1 (en) 2017-04-28 2020-03-04 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
WO2018209158A2 (en) 2017-05-10 2018-11-15 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN110997908A (zh) 2017-06-09 2020-04-10 爱迪塔斯医药公司 工程化的cas9核酸酶
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
KR102424850B1 (ko) 2017-06-30 2022-07-22 인스크립타 인코포레이티드 자동 세포 처리 방법, 모듈, 기기 및 시스템
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
CA3073662A1 (en) 2017-08-22 2019-02-28 Napigen, Inc. Organelle genome modification using polynucleotide guided endonuclease
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
AU2018338990B2 (en) 2017-09-30 2022-06-23 Inscripta, Inc. Flow through electroporation instrumentation
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
EP3724214A4 (en) 2017-12-15 2021-09-01 The Broad Institute Inc. SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
WO2019157326A1 (en) 2018-02-08 2019-08-15 Zymergen Inc. Genome editing using crispr in corynebacterium
SG11202008956XA (en) 2018-03-14 2020-10-29 Editas Medicine Inc Systems and methods for the treatment of hemoglobinopathies
EP3775159A4 (en) 2018-03-29 2022-01-19 Inscripta, Inc. AUTOMATED REGULATION OF CELL GROWTH RATES FOR INDUCTION AND TRANSFORMATION
WO2019200004A1 (en) 2018-04-13 2019-10-17 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
WO2019209926A1 (en) 2018-04-24 2019-10-31 Inscripta, Inc. Automated instrumentation for production of peptide libraries
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
CA3104856A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
AU2019292919A1 (en) 2018-06-30 2021-03-11 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US10752874B2 (en) 2018-08-14 2020-08-25 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
WO2020081149A2 (en) 2018-08-30 2020-04-23 Inscripta, Inc. Improved detection of nuclease edited sequences in automated modules and instruments
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
WO2020086475A1 (en) 2018-10-22 2020-04-30 Inscripta, Inc. Engineered enzymes
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CA3129871A1 (en) 2019-03-08 2020-09-17 Zymergen Inc. Iterative genome editing in microbes
US11053515B2 (en) 2019-03-08 2021-07-06 Zymergen Inc. Pooled genome editing in microbes
JP2022524044A (ja) * 2019-03-08 2022-04-27 ザイマージェン インコーポレイテッド 微生物のプール型ゲノム編集
DE112020001306T5 (de) 2019-03-19 2022-01-27 Massachusetts Institute Of Technology Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
EP3947691A4 (en) 2019-03-25 2022-12-14 Inscripta, Inc. SIMULTANEOUS MULTIPLEX GENOME EDITING IN A YEAST
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN113939593A (zh) 2019-06-06 2022-01-14 因思科瑞普特公司 用于递归的核酸指导的细胞编辑的处治
US10907125B2 (en) 2019-06-20 2021-02-02 Inscripta, Inc. Flow through electroporation modules and instrumentation
CN114008070A (zh) 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021102059A1 (en) 2019-11-19 2021-05-27 Inscripta, Inc. Methods for increasing observed editing in bacteria
US10883095B1 (en) 2019-12-10 2021-01-05 Inscripta, Inc. Mad nucleases
US10704033B1 (en) 2019-12-13 2020-07-07 Inscripta, Inc. Nucleic acid-guided nucleases
CN114829607A (zh) 2019-12-18 2022-07-29 因思科瑞普特公司 用于体内检测核酸引导的核酸酶编辑的细胞的Cascade/dCas3互补测定
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
WO2021154706A1 (en) 2020-01-27 2021-08-05 Inscripta, Inc. Electroporation modules and instrumentation
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
EP4214314A4 (en) 2020-09-15 2024-10-16 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
US11306298B1 (en) 2021-01-04 2022-04-19 Inscripta, Inc. Mad nucleases
US11332742B1 (en) 2021-01-07 2022-05-17 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
US11884915B2 (en) 2021-09-10 2024-01-30 Agilent Technologies, Inc. Guide RNAs with chemical modification for prime editing

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010131014A (ja) 1998-07-15 2010-06-17 Maxygen Inc 繰返し配列組換えによる細胞全体および生物の進化
US20130052646A1 (en) 2009-08-10 2013-02-28 Mascoma Corporation Positive and negative selectable markers for use in thermophilic organisms
JP2013520989A (ja) 2010-03-05 2013-06-10 シンセティック ジェノミクス インコーポレーテッド ゲノムのクローニングおよび操作のための方法
JP2015523856A (ja) 2012-05-25 2015-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフ Ｒｎａ依存性標的ｄｎａ修飾およびｒｎａ依存性転写調節のための方法および組成物
JP2016514480A (ja) 2013-04-05 2016-05-23 ダウ アグロサイエンシィズ エルエルシー 植物のゲノム内に外因性配列を組み込むための方法および組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935357A (en) 1986-02-05 1990-06-19 New England Biolabs, Inc. Universal restriction endonuclease
AU3391900A (en) * 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
DE60222914T2 (de) * 2001-07-27 2008-07-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden
US20100076057A1 (en) * 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
CN102858985A (zh) 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
AR080340A1 (es) * 2009-09-25 2012-04-04 Crop Functional Genomics Ct Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas mediante la modulacion de la expresion de sgt-1, clcpkg o un polipeptido tipo hd-hidrolasa
KR101656236B1 (ko) * 2012-10-23 2016-09-12 주식회사 툴젠 표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
EP2931899A1 (en) * 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010131014A (ja) 1998-07-15 2010-06-17 Maxygen Inc 繰返し配列組換えによる細胞全体および生物の進化
US20130052646A1 (en) 2009-08-10 2013-02-28 Mascoma Corporation Positive and negative selectable markers for use in thermophilic organisms
JP2013520989A (ja) 2010-03-05 2013-06-10 シンセティック ジェノミクス インコーポレーテッド ゲノムのクローニングおよび操作のための方法
JP2015523856A (ja) 2012-05-25 2015-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフ Ｒｎａ依存性標的ｄｎａ修飾およびｒｎａ依存性転写調節のための方法および組成物
JP2016514480A (ja) 2013-04-05 2016-05-23 ダウ アグロサイエンシィズ エルエルシー 植物のゲノム内に外因性配列を組み込むための方法および組成物

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ＢＭＣ Ｍｏｌ．Ｂｉｏｌ．，７：３４（２００６）
Ｎａｔｕｒｅ Ｂｉｏｔｅｃｈ．，ｖｏｌ．３１，ｐｐ．２３３－２４１（２０１３）
Ｎａｔｕｒｅ，ｖｏｌ．４６０，ｐｐ．８９４－８９８（２００９）
Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓ．，ｖｏｌ．４１，ｐｐ．４３３６－４３４３（２０１３）
Ｓｃｉｅｎｃｅ，ｖｏｌ．３３７，ｐｐ．８１６－８２１（２０１２）
Ｓｃｉｅｎｃｅ，ｖｏｌ．３３９，ｐｐ．８１９－８２３（２０１３）
Ｓｃｉｅｎｃｅ，ｖｏｌ．３３９，ｐｐ．８２３－８２６（２０１３）

Also Published As

Publication number Publication date
CA2917638C (en) 2024-09-10
AU2014287393B2 (en) 2020-10-22
ES2929143T3 (es) 2022-11-25
JP7676351B2 (ja) 2025-05-14
EP3019616A4 (en) 2017-01-11
RU2019135885A3 (enExample) 2020-05-28
NZ754833A (en) 2021-09-24
RU2706562C2 (ru) 2019-11-19
EP4166669A1 (en) 2023-04-19
RU2764637C2 (ru) 2022-01-19
SG11201600059QA (en) 2016-02-26
IL303973A (en) 2023-08-01
JP2016523559A (ja) 2016-08-12
JP7201294B2 (ja) 2023-01-10
IL243475A0 (en) 2016-03-31
KR20230122182A (ko) 2023-08-22
AU2021200288A1 (en) 2021-03-18
SG10201800111SA (en) 2018-02-27
JP2024109929A (ja) 2024-08-14
KR20160029112A (ko) 2016-03-14
RU2016104056A3 (enExample) 2018-03-21
RU2016104056A (ru) 2017-08-14
CN105518144A (zh) 2016-04-20
AU2023202363B2 (en) 2025-06-26
AU2021200288B2 (en) 2023-01-19
WO2015006290A1 (en) 2015-01-15
EP3019616B1 (en) 2022-10-12
CA3192673A1 (en) 2015-01-15
HK1217967A1 (en) 2017-01-27
IL243475B2 (en) 2023-11-01
US20160168592A1 (en) 2016-06-16
SG10201913026TA (en) 2020-02-27
EP3019616A1 (en) 2016-05-18
AU2014287393A1 (en) 2016-02-04
JP2020062044A (ja) 2020-04-23
CN116042726A (zh) 2023-05-02
NZ716604A (en) 2021-09-24
KR20220025922A (ko) 2022-03-03
CA2917638A1 (en) 2015-01-15
RU2019135885A (ru) 2019-12-19
US11459585B2 (en) 2022-10-04
US20220380811A1 (en) 2022-12-01
AU2023202363A1 (en) 2023-05-11
JP2023021447A (ja) 2023-02-10
IL243475B1 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
JP7676351B2 (ja) 多重ｒｎａ誘導型ゲノム編集
JP7036512B2 (ja) 巨大遺伝子の切除および挿入
US9074199B1 (en) Mutant Cas9 proteins
HK40092154A (en) Multiplex rna-guided genome engineering
HK1217967B (en) Multiplex rna-guided genome engineering
NZ754833B2 (en) Multiplex rna-guided genome engineering
Church et al. Multiplex RNA-guided genome engineering
NZ716604B2 (en) Multiplex rna-guided genome engineering
BR112016000564B1 (pt) Método de produzir múltiplas alterações ao dna alvo
HK40023048A (en) Large gene excision and insertion
HK1229380A1 (en) Large gene excision and insertion
HK1229380B (en) Large gene excision and insertion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191227

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191227

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200311

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200317

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200619

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200623

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200915

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210629

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211022

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211109

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220126

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220208

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220607

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220705

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220802

R150 Certificate of patent or registration of utility model

Ref document number: 7120717

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250